Back to Careers

Juvena’s CMO Dr. Barney King participates in the Myotonic Dystrophy Regional Summit, where Juvena gave an industry presentation.

Back to Careers

CEO Dr. Hanadie Yousef participates in a panel on “Demystifying Aging” at Horizons Ventures 2024 Techcracker summit 

Back to Careers

Juvena CEO and CO-Founder Dr. Hanadie Yousef featured in San Francisco Business Times article highlighting women biotech leaders

Back to Careers

Ashil Koranne presented a poster at the 2024 MDA Clinical & Scientific Conference highlighting Juvena Therapeutics’ promising preclinical development of JUV-161, a novel fusion protein for treating Myotonic Dystrophy Type 1.

Back to Careers

Juvena recognized by The Wall Street Journal for developing regenerative therapies aimed at weight loss and prevention of muscle wasting

Back to Careers

Juvena gets FDA Orphan Drug nod for muscle regeneration therapy

Back to Careers

Juvena’s JUV-161 awarded US orphan drug designation for myotonic dystrophy type 1

Back to Careers

Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1

Back to Careers

Juvena Therapeutics is recognized in Biospace’s Top 30 list, “NextGen Class of 2024: Top Life Sciences Startups to Watch This Year”